U.S. FDA Warns Eisai’s Epilepsy Drug Could Risk Kidney, Bone Problems
This article was originally published in PharmAsia News
Eisai's Zonegran (zonisamide) took a hit from U.S. FDA when the agency warned the epilepsy drug could increase the risk of kidney stones and bone disease. The drug, also sold as a generic, is approved for partial seizures in adult epilepsy patients in combination with other medications. FDA advised physicians Zonegran could cause metabolic acidosis, which leads to the other problems. The agency said it was requiring Eisai and generics makers to add the risk to a warning label, which would advise they be tested for the condition during treatment. (Click here for more - a subscription may be required
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.